Business Wire

Snow Software Introduces Snow Atlas

1.7.2021 12:00:00 CEST | Business Wire | Press Release

Share

Snow Software, the global leader in technology intelligence, today announced Snow Atlas, the first integrated platform built from the ground up to help organizations discover, monitor and optimize their technology investments, both on-premises and in the cloud. The first solutions available on the new cloud-native platform are software asset management (SAM), software-as-a-service (SaaS) management and IT service management (ITSM) integrations delivered as a service, now in early access.

The introduction of Snow Atlas marks a significant milestone for the company, as it establishes a new way to access Snow’s award-winning technologies and is accompanied by a significant increase in product investment.

“The introduction of Snow Atlas is the next step in our journey to enable organizations to realize the full potential of technology intelligence,” said Vishal Rao, President and CEO of Snow Software. “The platform provides a new way for the hybrid enterprise to manage cost, minimize risk and optimize technology investments. But just as importantly, we view Snow Atlas as the foundation for future innovation that supports the evolving needs of our customers. As such, we are substantially increasing the investment in our product development capacity to rapidly accelerate our innovation agenda.”

A unified platform for complete visibility and manageability

Based on the demand to consume technologies as a service, Snow Atlas is a cloud-native platform built on Microsoft Azure delivered as a service. The platform is based on a microservices architecture and standardized APIs to enable faster innovation and flexibility. Built into Snow Atlas are self-service features such as self-healing for locked or disconnected services, real-time agent creation, end-user management, single sign-on activation and in-app guidance. Customers will also benefit from the latest features and capabilities with Snow’s continuous delivery pipeline.

Snow Atlas is designed to provide organizations with a faster time to value, improved overall experience, improved ROI and enhanced business agility. As the first solution available on the new platform, SAM on Snow Atlas empowers organizations to:

  • Discover and inventory technology assets running across the ecosystem
  • Manage and optimize the use of enterprise software and SaaS applications
  • Reduce technology spend by reassigning licenses or access as needed
  • Minimize risks caused by compliance and security issues
  • Integrate technology data across the enterprise ecosystem

SAM on Snow Atlas is now available worldwide in early access, with general availability expected later in 2021. Snow will continue to offer options for on-premises and partner-hosted services.

Doubling down on innovation

To fuel future innovation on the platform and introduce new capabilities faster, Snow is preparing to double its product development capacity by increasing its overall investment in R&D and engineering.

“For most organizations, including ourselves, 2020 was a year of profound change that required a focus on stability and resiliency,” said Rao. “As we look at the opportunity ahead and consider the continued evolution of the market, we believe that it is essential to aggressively invest in the future of our technologies. Global organizations need solutions that can help them sort through the decisions from the past year and optimize spend to accelerate growth. And we want to ensure that we can offer new ways for organizations to realize these business outcomes by expediting our roadmap to help our customers seize the opportunity head on.”

This announcement follows several notable achievements for Snow over the past year, which include surpassing $100M ARR, rolling out a new partner program, expanding the strategic alliance with BMC and launching the inaugural Technology Intelligence Awards.

For more information on Snow Atlas, please visit https://www.snowsoftware.com/blog/new-snow-exploring-snow-atlas-platform.

About Snow Software

Snow Software is changing the way organizations understand and manage their technology consumption. Our technology intelligence platform provides comprehensive visibility and contextual insight across software, SaaS, hardware and cloud. With Snow, IT leaders can effectively optimize resources, enhance performance and enable operational agility in a hybrid world. To learn more, visit www.snowsoftware.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PR Contact:
Julie Neumann
Snow Software
julie.neumann@snowsoftware.com
+1 615 498 9650

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press Release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press Release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press Release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye